NasdaqCM - Nasdaq Real Time Price USD

ZyVersa Therapeutics, Inc. (ZVSA)

0.5064
-0.0165
(-3.18%)
As of 10:28:44 AM EDT. Market Open.
All All Favorites Text Statistics Technicals Fibonacci Markings Lines
Loading Chart for ZVSA

Recent News: ZVSA

View More
ZyVersa Therapeutics Reports First Quarter 2025 Financial Results and Highlights Pipeline Progress

ZyVersa Therapeutics Reports First Quarter 2025 Financial Results and Highlights Pipeline Progress
GlobeNewswire 6 days ago
ZyVersa Unveils Groundbreaking Potential of Inflammasome Inhibitors in Combination with GLP-1 Agonists to Address Unmet Medical Needs of People Living with Obesity; Provides R&D Update

ZyVersa Unveils Groundbreaking Potential of Inflammasome Inhibitors in Combination with GLP-1 Agonists to Address Unmet Medical Needs of People Living with Obesity; Provides R&D Update
GlobeNewswire 12 days ago
ZyVersa Therapeutics Announces Published Data Showing Inflammasome ASC Inhibitor IC 100 Decreases Microglial Inflammasome Activation and Alpha-Synuclein That Contribute to Neurodegeneration in Parkinson’s Disease

ZyVersa Therapeutics Announces Published Data Showing Inflammasome ASC Inhibitor IC 100 Decreases Microglial Inflammasome Activation and Alpha-Synuclein That Contribute to Neurodegeneration in Parkinson’s Disease
GlobeNewswire 20 days ago
ZyVersa Therapeutics CEO Issues Shareholder Letter Announcing Transformative R&D Trends for Inflammasome Inhibitors, and Provides Update on Inflammasome ASC Inhibitor IC 100’s Development Status

ZyVersa Therapeutics CEO Issues Shareholder Letter Announcing Transformative R&D Trends for Inflammasome Inhibitors, and Provides Update on Inflammasome ASC Inhibitor IC 100’s Development Status
GlobeNewswire 25 days ago
Why ZyVersa Therapeutics, Inc. (ZVSA) Went Down On Thursday?

Why ZyVersa Therapeutics, Inc. (ZVSA) Went Down On Thursday?
Insider Monkey last month
ZyVersa Therapeutics CEO Issues Shareholder Letter on PARASOL Recommendations Expected to Reduce Drug Development Barrier for Rare Kidney Disease, Focal Segmental Glomerulosclerosis (FSGS)

ZyVersa Therapeutics CEO Issues Shareholder Letter on PARASOL Recommendations Expected to Reduce Drug Development Barrier for Rare Kidney Disease, Focal Segmental Glomerulosclerosis (FSGS)
GlobeNewswire last month
ZyVersa Therapeutics Reports Full Year 2024 Financial Results and Provides Business Update

ZyVersa Therapeutics Reports Full Year 2024 Financial Results and Provides Business Update
GlobeNewswire last month
ZyVersa Therapeutics Highlights Data Published in the Journal of the American Heart Association Demonstrating Inflammasome Inhibition Attenuates Obesity-Associated Cardiomyopathy in Animal Model Study

ZyVersa Therapeutics Highlights Data Published in the Journal of the American Heart Association Demonstrating Inflammasome Inhibition Attenuates Obesity-Associated Cardiomyopathy in Animal Model Study
GlobeNewswire 2 months ago
ZyVersa Therapeutics Highlights Data Demonstrating Inflammasome Inhibition Reduces Neuroinflammation and Pathological Brain Deposition of Amyloid Beta in Alzheimer’s Disease Mouse Model

ZyVersa Therapeutics Highlights Data Demonstrating Inflammasome Inhibition Reduces Neuroinflammation and Pathological Brain Deposition of Amyloid Beta in Alzheimer’s Disease Mouse Model
GlobeNewswire 2 months ago
ZyVersa Therapeutics, Inc. Announces Pricing of $2.0 Million Private Placement Priced At The Market

ZyVersa Therapeutics, Inc. Announces Pricing of $2.0 Million Private Placement Priced At The Market
GlobeNewswire 2 months ago
ZyVersa Therapeutics Highlights Data Demonstrating NLRP3 Inflammasome Inhibition Reduces Inflammation, Improves Heart Function, and Restores Glucose Homeostasis and Insulin Sensitivity in Obese Animal Model of Heart Failure (HFpEF) and Type 2 Diabetes

ZyVersa Therapeutics Highlights Data Demonstrating NLRP3 Inflammasome Inhibition Reduces Inflammation, Improves Heart Function, and Restores Glucose Homeostasis and Insulin Sensitivity in Obese Animal Model of Heart Failure (HFpEF) and Type 2 Diabetes
GlobeNewswire 2 months ago
View More

Related Tickers

SPRC SciSparc Ltd.
0.3081
-2.12%
 
SXTP 60 Degrees Pharmaceuticals, Inc.
2.3750
-3.85%
 
CDIO Cardio Diagnostics Holdings, Inc.
4.0006
+4.16%
 
HEPA Hepion Pharmaceuticals, Inc.
0.1060
-3.90%
 
AZTR Azitra, Inc.
0.2746
+1.67%
 
DRMA Dermata Therapeutics, Inc.
0.7908
-0.03%
 
KTTA Pasithea Therapeutics Corp.
0.9200
-3.75%
 
INAB IN8bio, Inc.
0.1223
-4.97%
 
OCEA Ocean Biomedical, Inc.
0.0090
+5.88%
 
CDT Conduit Pharmaceuticals Inc.
0.3521
-9.69%